CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Index investing focuses on market-wide exposure with low fees and discipline. This snippet outlines why it appeals to many investors seeking consistency.
20,990 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
With SpaceX poised to hit the public markets, a wave of megadeals led by Elon Musk looms. Analysts warn the IPO could...
Nebius Group shows a dramatic jump in revenue as AI demand accelerates. This article explains the drivers, checks the...
Realtor.com's 2026 housing scorecards reveal the Midwest and Southern states dominate affordability and new-home cons...
A new AI narrative is taking shape. Nvidia Jensen Huang Just outlined a path where autonomous AI agents could transfo...
A well-known reality TV figure reveals how convincing fake security texts lured him into a crypto scam that wiped out...
Berkshire Hathaway disclosed a $2.65 billion stake in Delta Air Lines, marking a sharp shift from Buffett-era airline...
As rates trend higher, investors worry about income and growth. This article explores a dividend ETF designed to weat...
A single metric may reveal whether Nvidia will continue dominate in AI. This deep dive explains the number, the risks...
A GMAC survey finds AI is replacing entry-level roles for about one-third of employers, with tech and manufacturing t...
As markets wobble and political headwinds rise, a growing chorus argues that ceos have forgotten moderate. This piece...
A new study finds that companies investing heavily in AI per employee are expanding payrolls faster, with notable gai...